Receptor News and Research

RSS

Potential treatment approach to new COVID-19 variant

Researchers in the United States have demonstrated a potential new approach to treating infection with the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

7 Jan 2021

Researchers provide comprehensive molecular characterization of head and neck cancers

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

7 Jan 2021

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.

7 Jan 2021

Which strain should SARS-CoV-2 vaccine candidates target?

A researcher at Clemson University, USA, has recently explored how governments might effectively combat the pandemic through strategic vaccination as new variants and strains of the virus emerge. The study suggests that vaccine candidates should target the fast-spreading variant, even when the initial prevalence is much lower.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

7 Jan 2021

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

Scientists develop a new method to study the molecular characteristics of T cells

UT Southwestern scientists have developed a new method to study the molecular characteristics of T cells, critical immune cells that recognize and attack invaders in the body such as viruses, bacteria, and cancer.

6 Jan 2021

Researchers identify the missing link between intestinal disease and brain injury in premature infants

Physicians have long known that necrotizing enterocolitis (NEC), a potentially lethal inflammatory condition that destroys a premature infant's intestinal lining, is often connected to the development of severe brain injury in those infants who survive.

6 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

A new study shows the effectiveness of a novel recombinant vaccinia virus that expresses modified SARS-CoV-2 spike antigen, in preventing the replication of the virus in the respiratory tract of transgenic mice, and to prevent lethal disease.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Researchers reveal distinct molecular signature in tumor tissues of Black breast cancer patients

A Roswell Park Comprehensive Cancer Center team led by Christine Ambrosone, PhD, and Song Yao, PhD, has revealed a distinct molecular signature in the tumor tissues of Black patients with breast cancer.

5 Jan 2021

NCCN publishes new informational resources on health and wellness for cancer survivors

Today, the National Comprehensive Cancer Network announced the publication of new, free informational resources on health and wellness for cancer survivors.

5 Jan 2021

Debilitating gastrointestinal symptoms could be controlled with diet and lifestyle modifications

Findings from the Nurses' Health Study, one of the longest running studies of women's health, show that five diet and lifestyle factors, including regular exercise, can make a significant impact on gastroesophageal reflux (GERD) or heartburn symptoms.

5 Jan 2021

Repeated ketamine infusions may be a promising treatment for PTSD patients

Repeated intravenous (IV) ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a study conducted by researchers from the Icahn School of Medicine at Mount Sinai.

5 Jan 2021

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is essential for the shift in metabolic activity that occurs with T cell activation, making it a critical factor in regulating the anti-tumor immune response.

4 Jan 2021

USF researchers discover promising new compound to open constricted airways

Despite the progress made in managing asthma and chronic obstructive pulmonary disease (COPD), poorly controlled symptoms for both respiratory diseases can lead to severe shortness of breath, hospitalizations or even death.

4 Jan 2021

Receptor News and Research

Potential treatment approach to new COVID-19 variant

Researchers provide comprehensive molecular characterization of head and neck cancers

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Which strain should SARS-CoV-2 vaccine candidates target?

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

MD Anderson and Xencor to develop novel antibody therapeutics to treat cancer patients

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

In-silico modeling provides new understanding of immune response to SARS-CoV-2

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

Scientists develop a new method to study the molecular characteristics of T cells

Researchers identify the missing link between intestinal disease and brain injury in premature infants

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Are SARS-CoV-2 antibodies associated with disease enhancement?

Researchers reveal distinct molecular signature in tumor tissues of Black breast cancer patients

NCCN publishes new informational resources on health and wellness for cancer survivors

Debilitating gastrointestinal symptoms could be controlled with diet and lifestyle modifications

Repeated ketamine infusions may be a promising treatment for PTSD patients

Researchers discover protein crucial to T cell metabolism and anti-tumor immune response

USF researchers discover promising new compound to open constricted airways

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News